Cephalon Patent Suit Over Amrix Survives Dismissal

Law360, New York (March 15, 2010, 5:39 PM EDT) -- A federal judge has ruled that a patent infringement suit against Anchen Pharmaceuticals Inc. over its plans to make a generic version of Cephalon Inc. muscle relaxant Amrix can go forward, largely denying an Anchen dismissal motion in the case, which is part of a multidistrict litigation.

The plaintiffs — Amrix patent owner Eurand Inc. and Cephalon subsidiary and patent licensee Anesta AG — have raised a sufficient controversy to allow the case to go forward, Judge Sue Robinson of the U.S. District Court for the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.